Actuate Therapeutics, Inc. 8-K Filing
Ticker: ACTU · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1652935
| Field | Detail |
|---|---|
| Company | Actuate Therapeutics, Inc. (ACTU) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Actuate Therapeutics, Inc. (ticker: ACTU) to the SEC on Nov 21, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.000001 (ch registered Common Stock, par value $0.000001 per share ACTU The Nasdaq Stock Mar).
How long is this filing?
Actuate Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 567 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-11-21 16:30:42
Key Financial Figures
- $0.000001 — ch registered Common Stock, par value $0.000001 per share ACTU The Nasdaq Stock Mar
Filing Documents
- actuate_8k.htm (8-K) — 29KB
- 0001683168-25-008618.txt ( ) — 193KB
- actu-20251121.xsd (EX-101.SCH) — 3KB
- actu-20251121_lab.xml (EX-101.LAB) — 33KB
- actu-20251121_pre.xml (EX-101.PRE) — 22KB
- actuate_8k_htm.xml (XML) — 4KB
01 Other Information
Item 8.01 Other Information. Actuate Therapeutics Disclosure Channels to Disseminate Information Actuate Therapeutics' investors and others should note that we announce material information to the public about our company and its technologies, clinical and corporate developments, and other matters through a variety of means, including Actuate Therapeutics' website, press releases, SEC filings, and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations below as such information could be deemed to be material information. Please note that this list may be updated from time to time. Interested in keeping up with Actuate Therapeutics? For more information on Actuate Therapeutics and its technology, clinical and corporate developments, and other matters, please visit: https://actuatetherapeutics.com. For more information for Actuate Therapeutics' investors, including press releases, SEC filings, corporate presentations, events, please visit: https://actuatetherapeutics.com/investors. Investors and other interested parties can subscribe to our press releases and SEC filings at the aforementioned address. For additional information, please follow Actuate Therapeutics social media accounts at: X account (formerly Twitter): @ActuateThera or https://x.com/ActuateThera LinkedIn: https://www.linkedin.com/company/actuate-therapeutics-inc./ Facebook profile: https://www.facebook.com/profile.php?id=61572431561095 Investors and other interested parties can also subscribe to our social media accounts at the aforementioned addresses. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Actuate Therapeutics, Inc. Date: November 21, 2025 By: /s/ Daniel M. Schmitt Name: Daniel M. Schmitt Title: President and Chief Executive Officer 3